BioPharma Dive March 15, 2024
The company expects slow initial uptake of Rezdiffra, which costs $47,400 per year, but for the launch to accelerate afterwards.
The first drug for metabolic dysfunction-associated steatohepatitis will cost $47,400 per year, its developer, Madrigal Pharmaceuticals, said Thursday.
Madrigal revealed the price and launch plan for Rezdiffra on a conference call discussing the decision by the Food and Drug Administration to approve the medicine.
Rezdiffra is the first available therapy for MASH, a disease caused by a buildup of fat in the liver that leads to progressive organ damage. Its availability is a milestone in the fight against the condition, which has bedeviled drugmakers for about a decade.
MASH is projected to affect millions of people globally and...
Today's Sponsors
Today's Sponsor